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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition which is characterized by a
dramatic socio-economic impact.
Several indices were extensively investigated in order to asses the mortality risk in COPD, but the utilization of
health care resources was never included in calculations. The aim of this study was to assess the predictive value of
annual cost of care on COPD mortality at three years, and to develop a comprehensive index for easy calculation of
mortality risk in real life.
Methods: COPD patients were anonymously and automatically selected from the local institutional Data Base.
Selection criteria were: COPD diagnosis; both genders; age ≥ 40 years; availability of at least one complete clinical
record/year, including history; clinical signs; complete lung function, therapeutic strategy, health BODE index;
Charlson Comorbidity Index, and outcomes, collected at the first visit, and over the following 3-years. At the first
visit, the health annual cost of care was calculated in each patient for the previous 12 months, and the survival rate
was also measured over the following 3 years. The hospitalization and the exacerbation rate were implemented to
the BODE index and the novel index thus obtained was called BODECOST index (BCI), ranging from 0 to 10 points.
The mean cost for each BCI step was calculated and then compared to the corresponding patients’ survival
duration.
Parametrical, non parametrical tests, and linear regression were used; p < 0.05 was accepted as the lower limit of
significance.
Results: At the first visit, the selected 275 patients were well matched for all variables by gender. The overall
mortality over the 3 year survey was 40.4 % (n = 111/275). When compared to that of BODE index (r = 0.22), the
total annual cost of care and the number of exacerbations showed the highest regression value vs the survival time
(r = 0.58 and r = 0.44, respectively). BCI score proved strictly proportional to both the cost of care and the survival
time in our sample of COPD patients.
Discussion: BCI takes origin from the implementation of the BODE index with the two main components of the
annual cost of care, such as the number of hospitalizations and of exacerbations occurring yearly in COPD patients,
and their corresponding economic impact. In other words, higher the BCI score, shorter the survival and higher the
cost, these trends being strictly linked.
Conclusions: BCI is a novel composite index which helps in predicting the impact of COPD at 3 years in real life,
both in terms of patients’ survival and of COPD economic burden.
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Background
Chronic obstructive pulmonary disease (COPD) is the
chronic respiratory condition that currently represents
the most significant health problem at international
level [1]. The epidemiological, clinical and socio-
economic impact of COPD still is constantly increas-
ing, and COPD is projected to be the 3rd leading
cause of death in the world by 2030, and the 7th as a
burden of disease [2].
Chronic Obstructive Pulmonary Disease (COPD) is a
progressive condition which is characterized by a dra-
matic socio-economic impact [3, 4]. The role of clinical
signs, lung function, imaging, biological pictures, and
multiple scores (BODE index and other composite indi-
ces, such as, BODEx; BODEm; BODEi) was extensively
investigated in order to asses the mortality risk in
COPD, but with variable results due to their different
specificity and sensitivity [5–19].
Even if all these indices have contributed to clarify the
different clinical patterns of COPD patients at different
risk, the utilization of health care resources was never
included, to our knowledge, in the calculation of the
mortality risk of these patients.
The aim of this study was to assess the predictive
value of COPD annual cost of care on mortality at 3
years, and to develop a comprehensive index for the easy
calculation of mortality risk in real life.
Methods
The sample
The study sample was anonymously and automatically
selected [20] from the local institutional Data Base
(period 2008–2012), and selection criteria were: COPD
subjects of both genders; age ≥ 40 years; availability of at
least one complete clinical record/year, including their
history; clinical signs; complete lung function, thera-
peutic strategy, health BODE index; Charlson Comor-
bidity Index, and outcomes, collected at the first visit,
and over the following 3-years [4].
At the first visit, the health annual cost (direct and
indirect cost) was calculated in 275 consecutive COPD
patients for the previous 12 months, and their survival
was also calculated over the following 3 years.
As the impact is mainly related to the hospitalization
and the exacerbation rate per year in these patients, the
corresponding values were graded and implemented to
the BODE index [6], according to the algorithm reported
in Table 1. The novel index thus obtained was called
BODECOST index (BCI), ranging from 0 to 10 points
and from 1 to 4 severity (such as, 0–2; 3–4; 5–6, and 7–
10 points).
The mean cost for each BCI step was calculated stem-
ming from original data already published in a previous
study [4], and then compared to the corresponding
patients’ survival (in days) for each BCI step. Finally, the
rate of cost by BCI step was also calculated in the whole
sample of COPD patients.
Statistics
Parametrical and non parametrical tests were used for
comparing means ± sd; 95 % CI (Confidence Interval)
was also calculated. Any relationship between collected
variables vs the annual total COPD cost and survival
were assessed by linear regression, and p < 0.05 was ac-
cepted as the lower limit of significance. Calculations for
assessing the sensitivity of the novel composite index
were based on the data from reference 4.
The present study is a spontaneous research, without
any founding, and no conflict of interest to declare.
Results
The general profile of the whole sample (n = 275; males
n = 226; females n = 49) is reported in Table 2 for all var-
iables of the study. At the first visit, patients of both
genders were well matched for age, dyspnea, BODE
index, lung function, Charlson Comorbiditiy Index (all
p = ns). Males had slight, but significant, higher values of
Table 1 The algorithm for the BODECOST index (BCI)
variables score
0 1 2 3
BODE index 0–2 3–4 5–6 7–10
Hospitalizations (n/y) 0 1 2 >2
Exacerbations (n/y) 0–1 2 >2
Table 2 The sample profile
The whole sample (n = 275)
age (y) 70.9 ± 8.4
BMI 26.8 ± 4.6
smoking habit
active 65 (23.6 %)
ex 184 (66.9 %)
never smoker 26 (9.5 %)
FEV1 (I) 1.5 ± .05
FEV1 % pred, 55.9 ± 18.8
FEV1/FVC (%) 55.9 ± 10.3
FEV1/VC 51.1 ± 10.6
RV % pred. 156.9 ± 46.2
TLCO/VA % pred 70.9 ± 26.2
FEV1 reversibility 6.7 ± 7.9
6’ walking test (mt) 233.3 ± 92.7
MRC score 2.3 ± 1.2
BODE index 4.4 ± 2.6
Charlson comorb. index 3.3 ± 1.8
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FEV1 (1.5 L ±0.5sd vs 1.2 L ±0.5sd, respectively; p <
0.001) and BMI than females (27.1 ± 4.6sd VS 25.1 ±
4.3sd, respectively; p < 0.006), due to their mean size.
Males also had a more evident history of smoke (active
smokers 36.7 % vs 20.8 %, and never smokers 5.7 % vs
26.6 %, respectively).
Patients’ distribution according to GOLD guidelines was:
GOLD I = 11.6 %( n = 32); GOLD II = 48.4 % (n = 133);
GOLD III = 32.7 % (n = 90), and GOLD IV = 7.3 % (n = 20),
and it was well matched by gender.
The overall mortality over the 3 year survey was
40.4 % (n = 111/275), such as: 91/111 (82.0 % in males
(n = 91/111), and 18.0 % (20/111) in females, respect-
ively. Mean survival for subjects who deceased over the
3-year period was 676 days instead of 1095 for survivors.
The mean exacerbation rate/patient/year was 1.2 and
1.4 in survivors and in those who died over the 3 years,
respectively (+16.7 %). When adjusted for the effective
survival duration, the latter switched up to 2.3, and the
difference vs that of survivors became substantially
higher (+91.7 %).
Correspondingly, the hospitalization rate/patient/year
was 0.5 and 0.8 in survivors and in those who died over
the 3 years, respectively (+60.0 %). When adjusted for
the survival duration, the latter switched up to 1.3, and
the difference vs that of survivors highly increased
(+160.0 %).
The total annual cost of care and the number of exac-
erbations showed the highest regression value vs the sur-
vival time (r = 0.58 and r = 0.44, respectively) (Table 3),
such as, higher than that of age and that of BODE index.
Table 4 reports the progression of cost due to hospital-
izations + exacerbations, and the survival duration
(means ± sd) by the different BCI severity steps. It ap-
pears very clear that BCI score proves strictly propor-
tional to both the cost of care and the survival time in
our sample of COPD patients, even if it is directly pro-
portional in the former, and inversely proportional in the
latter case.
Discussion
Identifying the risk of mortality in COPD patients still
represents a crucial and strategic issue in COPD man-
agement. Many aspects had been focused in several
studies which used a single physiological measure of
lung function (i.e. FEV1) [21, 22], rather than complex
clinical assessments [8, 12, 23–27], or multidimensional
scores [6, 7, 9, 13, 14, 19].
These investigational approaches consented a continu-
ous improvement in the overall definition of COPD
mortality risk because several domains had been pro-
gressively investigated and valued.
Nevertheless, a wide variability is still persisting,
mainly due to the different role played by the variables
used in the various studies. FEV1 represents the first and
the most used variable adopted for predicting COPD
mortality [2–22], even if it does not fully mirror the
huge complexity of pathogenetic, clinical and functional
phenomena related to COPD survival [6].
Also the progression, the prognosis, and consequently
the mortality risk in COPD can not be fully explained by
the sole FEV1 measurement [1].
In general, the introduction of multidimensional grad-
ing systems improved the sensitivity of the mortality risk
assessment in COPD patients because, even if at differ-
ent level of specificity, these instruments valued several
factors affecting COPD severity and prognosis.
In particular, BODE index (such as, BMI, obstruction,
dyspnea, exercise) [6] proved to be the most sensitive
and specific from this point of view [9] when compared
to other similar multidimensional indices (such as,
ADO: age, dyspnea, obstruction; DOSE: dyspnea, ob-
struction, smoking, exacerbations) [13].
The COPD annual cost of care (or its major compo-
nents) was never regarded as a feasible contribution in
the assessment of mortality risk in this kind of patients
to our knowledge, even if the cost of care should likely
represent the most comprehensive index which reflects
the very final result of all factors affecting COPD sever-
ity and progression.
Actually, data from the present study confirmed once
again that the BODE index is highly significantly related
to the length of survival (p < 0.001), even if this relation-
ship was modest (r = − 0.21), and a not negligible vari-
ability can be presumed when mortality was assessed
Table 3 Regressions vs survival duration (days)
Age p < 0.001 r = − 0.28
BODE p < 0.001 r = − 0.21
n. exacerbations p < 0.0001 r = − 0.44
n. hospitalizations p < 0.0001 r = − 0.32
TOTAL COST p < 0.0001 r = − 0.58
Table 4 The relationship between different levels of BCI score,
hospitalization + exacerbation cost, and survival (means ± sd)
BCI score Cost Exac. + Hosp(€)(mean ± sd) Survival(days)(mean ± sd)
0–2 494.8 1023.8
(n = 142) (1454.2) (198.9)
3–4 2040.9 889.5
(n = 66) (2079.0) 239.4
5–6 4952.9 762.2
(n = 36) (2265.3) (283.4)
7–10 9224.9 752.1
(n = 31) (7804.2) (226.7)
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only by means of the BODE index in our sample of
COPD patients.
On the other hand, both the hospitalization and the
exacerbation rates seemed more strictly related to the
length of survival (such as: r = − 0.32 and r = − 0.44, re-
spectively), and the corresponding costs showed the
same trend. Moreover, the total annual COPD cost of
care had the highest value for this relationship (r = −
0.58), thus suggesting a much closer correspondence be-
tween the annual cost of care and the survival at 3 years
in our COPD patients.
The hypothesis concerning the convenience of using
the cost of care in predicting COPD mortality at 3 years
seems clearly confirmed by the strict correspondence be-
tween the progression of the BCI score, the
hospitalization/exacerbation cost (which represents
more than 70 % of total annual cost), and the duration
of survival. In other words, higher the BCI score, shorter
the survival and higher the cost, these trends being
strictly linked.
Finally, BCI takes origin from the implementation of
the BODE index with the two main components of the
annual cost of care, such as the number of hospitaliza-
tions and of exacerbations occurring yearly in COPD pa-
tients. Actually, even if this information can suffer from
some variability mainly due to the inaccurate collection
of data, the BCI assessment does nor require per sè com-
plex measurements, because the implementation of the
annual rate of both hospital admissions and exacerba-
tions should be easy to collect and demonstrated by the
patient, as well as by the physician who can also easily
calculate the corresponding economic impact in his of-
fice. BCI definitively maintains the same simplicity of
BODE index, even if it provides more sensitive informa-
tion in terms of the patients’ mortality risk in clinical
practice.
The present paper has some weakness points, such as:
females only represented the 18 % of the sample. More-
over, both the sensitivity and the specificity of this novel
instrument of investigation should be confirmed on big-
ger population samples.
Conclusions
BCI is a novel and easy composite index which helps in
predicting the impact of COPD at 3 years in real life,
both in terms of patients’ survival and of COPD eco-
nomic burden.
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